1. Medtech Insight
  2. >>Device Area
  3. >>Diagnostics

Start-Up Spotlight: Cognoa Seeks Breakthrough In Early Diagnosis Of Autism And ADD

 
• By Reed Miller

US FDA recently granted Cognoa’s autism diagnostic device a Breakthrough Device designation to accelerate its efforts to get the first FDA-cleared medical device for the early diagnosis of autistic spectrum disorder (ASD) to market. The average age of ASD diagnosis is about four years old, but extensive clinical research has shown that earlier diagnosis of ASD can improve outcomes over the child’s lifetime. Cognoa’s system is intended to allow primary care physicians to diagnosis ASD in the children as young as 18 months.

Start-up Spotlight
• Source: shutterstock.com

Cognoa’s digital diagnostic platform is on track to be the first product cleared by US FDA for early diagnosis of autistic spectrum disorder (ASD).

The system applies machine learning and predictive analytics to diagnostic data and information provided by parents to allow pediatricians and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diagnostics

Tempus AI Buys Paige. AI For $81.25M To Help Build Largest Oncology Foundation Model

 
• By Marion Webb

Tempus expects its $81.25m acquisition of Paige AI to accelerate building the largest oncology foundation model. With its third deal this year, Tempus expands capabilities across genomics, pathology, and clinical trials.

A Decade Of Breakthrough Devices: Cardiac And Orthopedic Products Dominate FDA Designations

 
• By Brian Bossetta and Elizabeth Orr

The US FDA has provided an update on its breakthrough devices program, now 10 years running. Cardiac, orthopedic, and neurological devices have received the most designations, while only one has been awarded to an obstetrics/gynecology product.

Medtronic Posts Solid First-Quarter, Adds Board Members As Elliott Takes Stake

 
• By Marion Webb

Medtronic beat first-quarter revenue and EPS estimates, raised guidance, and added two board members and special committees as Elliott takes a stake.

Philips Announces Major Investment In US Manufacturing And Expansion Of Pennsylvania Facility

 
• By Brian Bossetta

Philips says the expansion of its facility in Reedsville, PA, will not only boost its capacity to produce AI-enabled ultrasounds that are used in hospitals across the US but will also create 120 well-paying jobs.

More from Device Area

Dexcom Nabs Weight Management Indication For Signos CGM

 
• By Malcolm Spicer

Signos links users to Dexcom’s Stelo for glucose readings and historic trends. The app is available in iOS and Android from the firm’s website, where it’s priced at $139 for three-month plan and $129 for a two-month plan, or online app stores.

SetPoint Medical Raises $140M: Pipeline Expansion And Multiple Sclerosis Clinical Trial On Horizon

 
• By Natasha Barrow

SetPoint Medical secured US FDA approval for its vagus nerve neuromodulation device to treat RA. Now, the start-up is tasked with convincing both rheumatologist and surgeons to adopt its technology over or alongside biologic drugs. CEO Murthy Simhambhatla talks exit strategy plans.

Alcon Drops Revenue Projections After Soft Q2 Sales

 
• By Elizabeth Orr

The vision company expects total annual revenues of $10.3bn-$10.4bn, marking a slower growth rate than earlier forecasts. However, management remains optimistic that overall trends, as well as recent purchases like STAAR and LumiThera, represent a significant market opportunity.